1. Home
  2. CRNX vs ANDG Comparison

CRNX vs ANDG Comparison

Compare CRNX & ANDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$42.21

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Andersen Group Inc. Class A Common Stock

ANDG

Andersen Group Inc. Class A Common Stock

N/A

Current Price

$36.64

Market Cap

4.1B

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
CRNX
ANDG
Founded
2008
2002
Country
United States
United States
Employees
N/A
52300
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.1B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
CRNX
ANDG
Price
$42.21
$36.64
Analyst Decision
Strong Buy
Buy
Analyst Count
8
7
Target Price
$76.75
$31.17
AVG Volume (30 Days)
1.3M
376.9K
Earning Date
05-07-2026
03-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,039,000.00
N/A
Revenue This Year
$720.10
$16.02
Revenue Next Year
$184.67
$13.67
P/E Ratio
N/A
$44.38
Revenue Growth
N/A
N/A
52 Week Low
$25.83
$18.12
52 Week High
$57.99
$40.23

Technical Indicators

Market Signals
Indicator
CRNX
ANDG
Relative Strength Index (RSI) 71.81 48.29
Support Level $38.68 $34.05
Resistance Level $44.89 $36.54
Average True Range (ATR) 1.71 2.28
MACD 0.74 -0.14
Stochastic Oscillator 97.89 37.96

Price Performance

Historical Comparison
CRNX
ANDG

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About ANDG Andersen Group Inc. Class A Common Stock

Andersen Group Inc is a provider of independent tax, valuation, and financial advisory services to individuals and family offices, businesses, and institutional clients in the United States. It has strategically expanded its business to build an integrated platform of service offerings that enables the company to solve its clients' complex tax and financial challenges. The company's end-to-end services offerings include: Private Client Services, Business Tax Services, Alternative Investment Funds, and Valuation Services. The firm generates the key revenue from Private Client Services, which provide comprehensive tax and financial services for individuals and families, addressing complex client matters involving multigenerational wealth, charitable giving, and trust and estate planning.

Share on Social Networks: